US Pneumococcal Vaccine Market Size, Share, Trend, Industry Analysis Report, By Vaccine Type, By Product Type (Prevnar 13, Synflorix, Pneumovax23), By End User, Market Forecast, 2025

Description

List of Tables

The US pneumococcal vaccine market size is expected to reach USD 6,511.79 million by 2034, according to a new study by Polaris Market Research. The report "US Pneumococcal Vaccine Market Size, Share, Trend, Industry Analysis Report, By Vaccine Type, By Product Type (Prevnar 13, Synflorix, Pneumovax23), By End User, Market Forecast, 2025 - 2034" gives a detailed insight into current market dynamics and provides analysis of future market growth.

The increasing number of patients with pneumonia in the US presents an opportunity for biotechnology companies to develop new pneumonia vaccines, which will contribute significantly to the growth of the US pneumococcal vaccine market.

The introduction of new drugs approved by the USFDA helps drive the market forward. For example, in May 2024, the FDA approved licenses for pneumococcal vaccines for use in the US, including Pneumovax 23, Prevnar 13, VAXNEUVANCE, and Prevnar 20. Pharmacists are well-positioned to provide recommendations for appropriate pneumococcal vaccinations, taking into account a patient's risk factors and vaccination history. Pharmacists are authorized to administer vaccines and assess patients to ensure they receive the appropriate vaccinations. To assist in making recommendations, pharmacists can use resources such as the CDC's mobile application, PneumoRecs VaxAdvisor.The increasing number of patients with pneumonia diseases in the US creates an opportunity for the biotechnology company to develop new pneumonia vaccines that significantly contribute to the US pneumococcal vaccine market growth.

For instance, in April 2024, Merck revealed positive data from the Phase III STRIDE-10 trial of V116, an investigational pneumococcal conjugate vaccine.

Ongoing innovation in pneumococcal vaccine formulations aims to improve efficacy and broaden protection against more strains of pneumococcal bacteria, including the development of next-generation conjugate vaccines that target additional serotypes (bacterial strains), offering enhanced immune response and longer-lasting protection. Companies such as Pfizer and Merck are working on new formulations that address emerging strains and reduce the risk of invasive pneumococcal diseases in vulnerable populations, such as children and old people. These innovations also aim to reduce dosing schedules, making vaccination more convenient and effective in large-scale immunization programs.

US Pneumococcal Vaccine Market Report Highlights

Prevnar 13 is the dominant pneumococcal vaccine in the United States by product type due to its broad protection against 13 strains of Streptococcus pneumonia, including those most commonly associated with severe infections.

The pneumococcal conjugate vaccine (PCV) segment is expected to witness the highest growth over the study period, owing to the increasing number of pneumococcal diseases.

The public sector dominates pneumococcal vaccine administration due to government immunization programs, widespread public healthcare infrastructure, and funding that ensures accessible, cost-effective vaccination. Disease prevention mandates further prioritize its use in hospitals and clinics.

The US pneumococcal vaccine market players are Pfizer Inc.; Merck & Co., Inc.; Novavax, Inc.; CSL Behring; and Johnson & Johnson.

Market Research has segmented the US pneumococcal vaccine market report based on vaccine type, product type, and end user:

By Vaccine Type Outlook (Revenue - USD Million, 2020 - 2034)

Pneumococcal conjugate vaccine
Pneumococcal polysaccharide vaccine

By Product Type Outlook (Revenue - USD Million, 2020 - 2034)

Prevnar 13
Synflorix
Pneumovax23

By End User Outlook (Revenue - USD Million, 2020 - 2034)

Public Sector
Private Sector

Product Code: PM5205

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. U.S. Viral Vector and Plasmid DNA Manufacturing Insights

4.1. U.S. Viral Vector and Plasmid DNA Manufacturing - Application Snapshot
4.2. U.S. Viral Vector and Plasmid DNA Manufacturing Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Increased Demand for Pneumococcal Vaccines is driving the US Pneumococcal Vaccines Market
  - 4.2.1.2. Aging Population is driving the US Pneumococcal Vaccines Market
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. Complex Vaccine Schedules
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. U.S. Viral Vector and Plasmid DNA Manufacturing Application Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. U.S. Viral Vector and Plasmid DNA Manufacturing, by Product Type

5.1. Key Findings
5.2. Introduction
- 5.2.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Product Type, 2020-2034 (USD million)
5.3. By Prevnar 13
- 5.3.1. U.S. Viral Vector and Plasmid DNA Manufacturing, By Prevnar 13, 2020-2034 (USD million)
5.4. Synflorix
- 5.4.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Synflorix, 2020-2034 (USD million)
5.5. Pneumovax23
- 5.5.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Pneumovax23, 2020-2034 (USD million)

6. U.S. Viral Vector and Plasmid DNA Manufacturing, by Vaccine Type

6.1. Key Findings
6.2. Introduction
- 6.2.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Vaccine Type, 2020-2034 (USD million)
6.3. Pneumococcal conjugate vaccine (PCV)
- 6.3.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Pneumococcal conjugate vaccine (PCV), 2020-2034 (USD million)
6.4. Pneumococcal polysaccharide vaccine (PPV)
- 6.4.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Pneumococcal polysaccharide vaccine (PPV), 2020-2034 (USD million)

7. U.S. Viral Vector and Plasmid DNA Manufacturing, by End Use

7.1. Key Findings
7.2. Introduction
- 7.2.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by End Use, 2020-2034 (USD million)
7.3. Public Sector
- 7.3.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Public Sector, 2020-2034 (USD million)
- 7.3.2. Private Sector
  - 7.3.2.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Private Sector, 2020-2034 (USD million)

8. Competitive Landscape

8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

9.1. Pfizer Inc.
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
9.2. Merck & Co. Inc.
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
9.3. Sanofi
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
9.4. GlaxoSmithKline plc
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
9.5. CSL Behring
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
9.6. Serum Institute
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
9.7. Astellas Pharma US, Inc.
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
9.8. Johnson & Johnson
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
9.9. Novavax, Inc.
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
9.10. Vaxcyte, Inc.
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development